Table 4.

Summary of articles on colorectal cancer.

Study	Chemotherapeutic Agent	Primary Investigation	Cohort Characteristics	Study cohort	Impact on OS	Impact on DFS	CC Coverage	PCI Coverage	Main Findings (with focus on peritoneal recurrence)
Klaver et al., 2019 (COLOPEC) (36)	Intraperitoneal oxaliplatin with adjuvant systemic fluorouracil and leucovorin	RCT CRS + systemic chemo + HIPEC vs CRS + systemic chemo	Advanced (T4N0-2M0) primary CC without PM	204	No significance in 18-month OS (93.0% in HIPEC vs 94.1% in control), p=0.82	No significance in 18-month DFS (69.0% in HIPEC vs 69.3% in control), p=0.99	Not covered	Not covered	No difference in peritoneal-free survival at 18-months (80.9% HIPEC vs 76.2% control), one-sided log-rank p=0.28.
Goere et al., 2020 (PROPHYLOCHIP) (37)	Oxaliplatin or oxaliplatin + irinotecan + IV fluorouracil or mitomycin-HIPEC	RCT CRS + systematic second-look surgery + HIPEC vs CRSa	Advanced primary CC with synchronous PM or established to be at high risk of subsequent PM	150	No significance in 3-year/5-year OS (79%/68% in HIPEC vs 80%/72% in control).	No significance in 3-year/5-year DFS (44%/42% in HIPEC vs 53%/49% in control), p=0.82/0.82	Not covered, 4 patients had advanced peritoneal disease not amenable to resection on second-look surgery	Not covered	No difference in 3-year peritoneal recurrence-free survival (59% HIPEC vs 61% CRSa),
Quenet et al., 2021 (PRODIGE 7) (38)	Oxaliplatin	RCT CRS + systemic chemo + HIPEC vs CRS + systemic chemo	Advanced primary CC with synchronous PM	265	No significance in median OS (41.7 in HIPEC vs 41.2 months in CRSa)	No significance in median RFS at 1 year (13.1 months in HIPEC vs 11.1 months in control), p=0.43	Completeness of cytoreduction was considered during randomization	Not randomized by PCI, though PCI ≤ 25 criteria was used for selection	No significant difference in peritoneal-free survival at 48 months (HR 0.908, 95CI 0.74-1.12), long-rank p=0.370. Median overall and relapse-free survival longer in subgroup of patients with PCI 11-15.